Grail's Cancer Detection Blood Test Stumbles After Super Bowl Ad

Silicon Valley company's innovative test fails to significantly reduce advanced cancer diagnoses in large clinical trial.

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

Grail, a Silicon Valley-based company, released results from a major clinical trial of its innovative blood test designed to detect cancer early. The test, called Galleri, was featured in a recent Super Bowl ad but the trial results showed it did not significantly reduce advanced cancer diagnoses as hoped. While Grail highlighted some positive findings, the company's stock plummeted 50% on the news.

Why it matters

Grail's blood test was seen as a promising new tool in the fight against cancer, with the potential to detect the disease at earlier, more treatable stages. The disappointing trial results raise questions about the real-world effectiveness of such 'liquid biopsy' tests and whether they can truly improve cancer outcomes, not just shift diagnoses to earlier stages.

The details

The clinical trial, conducted in collaboration with the UK's National Health Service, involved 142,000 people aged 50-77 who received annual blood tests for three years. While the trial missed its goal of a 20% reduction in Stage 3 and 4 cancer diagnoses across all cancer types, it did find a decrease in Stage 4 diagnoses and an increase in Stage 3 diagnoses for a subset of 12 cancer types. This suggests the test may enable earlier detection of some tumors, though it did not translate to an overall improvement in outcomes.

  • The Galleri blood test has been sold in the U.S. for just under $1,000 since 2021.
  • The clinical trial was launched in 2021, the same year Grail began selling the Galleri test.

The players

Grail

A Silicon Valley-based company that sells an innovative blood test designed to identify cancer early.

Ash Alizadeh

A researcher who leads the Stanford Cancer Institute's cancer genomics program.

Bob Ragusa

The CEO of Grail.

Got photos? Submit your photos here. ›

What they’re saying

“As the stock market reacted, I think those results are not sufficiently impressive to be transformative. It kind of breaks my heart to see the study be negative.”

— Ash Alizadeh, Researcher, Stanford Cancer Institute (SFGATE)

“We are excited to see the substantial reduction in Stage IV cancer diagnoses, as well as the continued strong Galleri test performance metrics. Based on these promising data, as well as the exciting PATHFINDER 2 results, we are expanding our field-based sales and medical teams to bolster our education efforts and support growing demand.”

— Bob Ragusa, CEO, Grail (SFGATE)

What’s next

The Food and Drug Administration has yet to approve the Galleri blood test, though doctors can currently order it under Clinical Laboratory Improvement Act regulations.

The takeaway

While Grail's Galleri test showed some promising results in detecting certain cancer types earlier, the overall failure to significantly reduce advanced cancer diagnoses in the large clinical trial raises doubts about the test's real-world effectiveness. This highlights the challenges of developing truly transformative cancer screening tools and the need for rigorous, long-term studies to validate their impact on patient outcomes.